Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease
September 11, 2022 09:45 ET
|
Relay Therapeutics, Inc.
88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose Enrollment for the pivotal...
Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
August 18, 2022 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 04, 2022 16:05 ET
|
Relay Therapeutics, Inc.
Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4008 at June...
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
July 28, 2022 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event
June 27, 2022 06:00 ET
|
Relay Therapeutics, Inc.
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma...
Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
June 16, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
May 26, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3rd Annual Oncology Innovation...
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
May 05, 2022 16:05 ET
|
Relay Therapeutics, Inc.
Initiated the fulvestrant combination arm of the first-in-human trial for RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, and continued to enroll patients in the single agent arm ...
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference
May 03, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference...
Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights
April 28, 2022 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...